Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors

被引:6
|
作者
Zeng, Li [1 ]
Ma, Gang [2 ,3 ]
Chen, Kai [1 ]
Zhou, Qiao [3 ,4 ]
机构
[1] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Neurol, Chengdu, Peoples R China
[2] Chengdu Univ Tradit Chinese Med, Chengdu, Peoples R China
[3] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Dept Rheumatol & Immunol, Chengdu, Peoples R China
[4] Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu, Peoples R China
来源
FRONTIERS IN IMMUNOLOGY | 2023年 / 14卷
关键词
immune checkpoint inhibitor; rheumatic immune-related adverse event; bibliometric; research trends; VOSviewer; CiteSpace; INDUCED SARCOIDOSIS; TUMOR RESPONSE; IMMUNOTHERAPY; AUTOIMMUNITY; NIVOLUMAB; BLOCKADE; ANTIBODY; CTLA4;
D O I
10.3389/fimmu.2023.1242336
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Immune checkpoint inhibitors (ICIs) has emerged as a popular cancer treatment approach. However, non-specific activation of T cells by ICIs can lead to immune-related adverse events (irAEs), including specific rheumatic manifestations. The study aimed to explore the current trend of ICIs associated rheumatic irAEs and summarize the knowledge structure through bibliometric methods.Methods The Web of Science Core Collection database (WoSCC) was selected for retrieving literature on ICIs associated rheumatic irAEs. To evaluate contributions from different countries/regions, institutions, journals, and authors, bibliometric analysis software, including VOSviewer and CiteSpace, as well as bibliometric online platforms, were utilized to construct and visualize bibliometric networks. Through the systematic review of this knowledge domain, future research directions were determined.Results In This study, a total of 803 publications on ICIs-associated rheumatic irAEs were included for analysis. The distribution of these publications revealed two distinct growth phases: a stable phase between 2007 to 2015 followed by rapid growth from 2016 to 2020. The United States emerged as the top contributor in terms of publications, citations, and h-index, with the majority of leading institutions and funding agencies located there. Apart from government funding, pharmaceutical companies such as Bristol Myers Squibb and Merck Company also play a significant role in drug development and research. Analysis of keywords and citation bursts indicated that the initial burst was related to "monoclonal antibody," "anti-CLTA4 antibody," and "melanoma". This was followed by a rise in interest related to "sarcoidosis," "safety," "inflammatory arthritis," and "preexisting autoimmune."Conclusion This study summarized the global research trends concerning ICIs associated rheumatic irAEs. The findings can provide valuable insights into the current understanding of rheumatic irAEs, highlight the research trend and developments in the field. Future efforts should focus on developing classification criteria and guidelines, conducting prospective studies, investigating the mechanisms involved, and identifying biomarkers for prediction and monitoring of these events.
引用
收藏
页数:13
相关论文
共 50 条
  • [21] The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
    Xiao-Hui Jia
    Lu-Ying Geng
    Pan-Pan Jiang
    Hong Xu
    Ke-Jun Nan
    Yu Yao
    Li-Li Jiang
    Hong Sun
    Tian-Jie Qin
    Hui Guo
    Journal of Experimental & Clinical Cancer Research, 39
  • [22] The biomarkers related to immune related adverse events caused by immune checkpoint inhibitors
    Jia, Xiao-Hui
    Geng, Lu-Ying
    Jiang, Pan-Pan
    Xu, Hong
    Nan, Ke-Jun
    Yao, Yu
    Jiang, Li-Li
    Sun, Hong
    Qin, Tian-Jie
    Guo, Hui
    JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2020, 39 (01)
  • [23] Immune-Related Adverse Events From Immune Checkpoint Inhibitors
    Marrone, K. A.
    Ying, W.
    Naidoo, J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (03) : 242 - 251
  • [24] In the Clinic Immune-Related Adverse Events of Immune Checkpoint Inhibitors
    Ramos-Casals, Manuel
    Siso-Almirall, Antoni
    ANNALS OF INTERNAL MEDICINE, 2024, 177 (02) : ITC17 - ITC32
  • [25] Immune Checkpoint Inhibitors and Immune-Related Adverse Renal Events
    Herrmann, Sandra M.
    Perazella, Mark A.
    KIDNEY INTERNATIONAL REPORTS, 2020, 5 (08): : 1139 - 1148
  • [26] Immune-related adverse events of immune checkpoint inhibitors: a review
    Yin, Qinan
    Wu, Liuyun
    Han, Lizhu
    Zheng, Xingyue
    Tong, Rongsheng
    Li, Lian
    Bai, Lan
    Bian, Yuan
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [28] Immune-related adverse events of checkpoint inhibitors
    Ramos-Casals, Manuel
    Brahmer, Julie R.
    Callahan, Margaret K.
    Flores-Chavez, Alejandro
    Keegan, Niamh
    Khamashta, Munther A.
    Lambotte, Olivier
    Marlette, Xavier
    Prat, Aleix
    Suarez-Almazor, Maria E.
    NATURE REVIEWS DISEASE PRIMERS, 2020, 6 (01)
  • [29] Checkpoint inhibitors and gastrointestinal immune related adverse events
    Pernot, Simon
    Ramtohul, Toulsie
    Taieb, Julien
    CURRENT OPINION IN ONCOLOGY, 2016, 28 (04) : 264 - 268
  • [30] Immune-related adverse events of checkpoint inhibitors
    Manuel Ramos-Casals
    Julie R. Brahmer
    Margaret K. Callahan
    Alejandra Flores-Chávez
    Niamh Keegan
    Munther A. Khamashta
    Olivier Lambotte
    Xavier Mariette
    Aleix Prat
    Maria E. Suárez-Almazor
    Nature Reviews Disease Primers, 6